In a speech at the Chief Executives Club of Boston, Eli Lilly and Company (NYSE: LLY) chairman and chief executive officer, Sidney Taurel, predicted that the coming biomedical revolution will move medicine from its current state of treating symptoms to predicting and preventing diseases.
Bristol-Myers Squibb Company (NYSE: BMY) today announced the company is expanding its research and development (R&D) capabilities in India. The increase is an integral part of the company?s overall R&D global strategy of accessing top-talent around the world in support of its goal of achieving sustainable, cost-effective growth.
Novartis has been ranked as the No. 1 company worldwide in the pharmaceuticals industry in the latest peer group results of the annual Fortune magazine survey of the “World’s Most Admired Companies.”
World diabetes leaders left the Global Changing Diabetes Leadership Forum, which took place in New York City on 13?14 March 2007, with a sense of activism to return home to start changing diabetes.
Opposition to current drug safety legislation is growing, as a group of 22 experts on drug safety and regulation and a coalition of 12 patient, consumer, science, and public health organizations issue two separate open letters to lawmakers.
A new method for analysis of retroviral proteins gives new opportunities to the development of novel retardants for HIV/Aids. The study, which was published in the March issue of PLoS Computational Biology, shows how to in a very exact way analyze the interaction of drug targets with small molecules.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDAfor Moexipril HCland HydrochlorothiazideTablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. Shipment of these products will begin immediately.
The decade-long research that University of Nevada, Reno College of Science Chemistry Professor Thomas Bell has invested in the development of an extremely effective HIV/AIDS-fighting compound received an important boost recently when one of Bell’s articles made the list of the 100 most influential publications in the HIV/AIDS research field for 2006.
Among the drugs that will be discussed in Amsterdam over the next three days are bevacizumab, cetuximab, dasatinib, erlotinib, lapatinib, nilotinib, oblimersen sodium, sorafenib, and sunitinib.
When searching for health advice online, consumers often reject Web sites with high quality medical information in favor of those with a human touch, according to new research funded by the Economic and Social Research Council.